Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Aravive, Inc.VSAR · Entity 114535 | Director | December 20, 2017 | December 22, 2017 |
| HYPERION DEFI, INC.EYEN · Entity 7220 | Director | November 17, 2021 | November 22, 2021 |
| Zentalis Pharmaceuticals, Inc.ZNTL · Entity 5772 | Director · President & CEO | April 04, 2022 | April 05, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Aravive, Inc.
Report date December 20, 2017 · Filed December 22, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 23,880 |
Reported balance
After 2017-12-20 transaction · row 1
1 source rowRow 1 · 2017-12-20 · Grant · Acquired 11,200 · Balance 23,880 F1: Represents the grant of restricted stock units that vest 100% on December 20, 2018. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents the grant of restricted stock units that vest 100% on December 20, 2018.
HYPERION DEFI, INC.
Report date November 17, 2021 · Filed November 22, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, par value $.0001SEC Table I · non-derivative | Direct | 26,322 |
Reported balance
After 2021-11-17 transaction · row 1
1 source rowRow 1 · 2021-11-17 · Grant · Acquired 6,963 · Balance 26,322 F1: Represents restricted stock units that fully vest on the earlier of November 17, 2022 or the date of the Issuer's 2022 annual meeting of stockholders, subject to the Reporting Person's continued service on the Issuer's Board of Directors and acceleration upon change in control. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.59 · Expires 2031-11-17 | Direct | 9,653 |
Reported balance
After 2021-11-17 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2021-11-17 · Grant · Acquired 9,653 · Balance 9,653 F2: The option becomes exercisable on the earlier of November 17, 2022 or the date of the Issuer's 2022 annual meeting of stockholders, subject to the Reporting Person's continued service on the Issuer's Board of Directors and acceleration upon change in control. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents restricted stock units that fully vest on the earlier of November 17, 2022 or the date of the Issuer's 2022 annual meeting of stockholders, subject to the Reporting Person's continued service on the Issuer's Board of Directors and acceleration upon change in control.
F2: The option becomes exercisable on the earlier of November 17, 2022 or the date of the Issuer's 2022 annual meeting of stockholders, subject to the Reporting Person's continued service on the Issuer's Board of Directors and acceleration upon change in control.
Zentalis Pharmaceuticals, Inc.
Report date April 04, 2022 · Filed April 05, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 1,175,589 |
Ending reported balance
After 2022-04-05 transaction · row 3
3 source rows · reconciled sequenceRow 1 · 2022-04-04 · Sale · Disposed 10,471 · Balance 1,186,060 F1: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 21, 2021. Row 2 · 2022-04-05 · Sale · Disposed 7,971 · Balance 1,178,089 F1: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 21, 2021. F2: The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $50.84 to $51.83. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Row 3 · 2022-04-05 · Sale · Disposed 2,500 · Balance 1,175,589 F1: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 21, 2021. F3: The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $51.85 to $52.70. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| Common StockSEC Table I · non-derivative | IndirectBy Spouse | 103,650 |
Reported balance
Holding disclosure · report date 2022-04-04 · row 4
Holding and transaction disclosures are not merged.
1 source rowRow 4 · Balance 103,650 |
| Common StockSEC Table I · non-derivative | IndirectBy Essex Group International, LLC | 974,302 |
Reported balance
Holding disclosure · report date 2022-04-04 · row 5
Holding and transaction disclosures are not merged.
1 source rowRow 5 · Balance 974,302 |
| Common StockSEC Table I · non-derivative | IndirectBy Hao Bao Zi Trust LLC | 213,600 |
Reported balance
Holding disclosure · report date 2022-04-04 · row 6
Holding and transaction disclosures are not merged.
1 source rowRow 6 · Balance 213,600 F4: Represents shares nominally held by Hao Bao Zi Trust LLC on behalf of the Hao Bao Zi Trust (the "Trust"), the sole member of Hao Bao Zi Trust LLC. The Reporting Person's spouse is the investment adviser with sole power to make investment decisions regarding the securities held by the Trust. The Reporting Person disclaims beneficial ownership of the securities held by Hao Bao Zi Trust LLC except to the extent of his pecuniary interest therein, if any. |
| Common StockSEC Table I · non-derivative | IndirectBy Hao Jiao Zi Trust LLC | 125,000 |
Reported balance
Holding disclosure · report date 2022-04-04 · row 7
Holding and transaction disclosures are not merged.
1 source rowRow 7 · Balance 125,000 F5: Represents shares nominally held by Hao Jiao Zi Trust LLC on behalf of the Hao Jiao Zi Trust (the "Trust"), the sole member of Hao Jiao Zi Trust LLC. The Reporting Person's spouse is the investment adviser with sole power to make investment decisions regarding the securities held by the Trust. The Reporting Person disclaims beneficial ownership of the securities held by Hao Jiao Zi Trust LLC except to the extent of his pecuniary interest therein, if any. |
Filing footnotes · ownership attribution and instrument terms
F1: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 21, 2021.
F2: The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $50.84 to $51.83. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F3: The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $51.85 to $52.70. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F4: Represents shares nominally held by Hao Bao Zi Trust LLC on behalf of the Hao Bao Zi Trust (the "Trust"), the sole member of Hao Bao Zi Trust LLC. The Reporting Person's spouse is the investment adviser with sole power to make investment decisions regarding the securities held by the Trust. The Reporting Person disclaims beneficial ownership of the securities held by Hao Bao Zi Trust LLC except to the extent of his pecuniary interest therein, if any.
F5: Represents shares nominally held by Hao Jiao Zi Trust LLC on behalf of the Hao Jiao Zi Trust (the "Trust"), the sole member of Hao Jiao Zi Trust LLC. The Reporting Person's spouse is the investment adviser with sole power to make investment decisions regarding the securities held by the Trust. The Reporting Person disclaims beneficial ownership of the securities held by Hao Jiao Zi Trust LLC except to the extent of his pecuniary interest therein, if any.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 04, 2021 Filed Jan 7, 2021 01:25 UTC | Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772 | SaleCommon Stock | 10,612 | $52.47 | $556,855.15 |
DisclosureSEC source: 0001725160-21-000008 · wf-form4_160998272301109.xml · nonDerivative · entry 5 SUN ANTHONY Y · CIK 0001377952 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,784,024 F2 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 22, 2020. F5 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $51.84 to $52.82. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| January 04, 2021 Filed Jan 7, 2021 01:25 UTC | Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772 | SaleCommon Stock | 3,951 | $51.41 | $203,103.53 |
DisclosureSEC source: 0001725160-21-000008 · wf-form4_160998272301109.xml · nonDerivative · entry 4 SUN ANTHONY Y · CIK 0001377952 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,794,636 F2 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 22, 2020. F4 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $50.83 to $51.81. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| January 04, 2021 Filed Jan 7, 2021 01:25 UTC | Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772 | SaleCommon Stock | 5,418 | $50.47 | $273,429.12 |
DisclosureSEC source: 0001725160-21-000008 · wf-form4_160998272301109.xml · nonDerivative · entry 3 SUN ANTHONY Y · CIK 0001377952 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,798,587 F2 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 22, 2020. F3 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $49.82 to $50.805. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| December 07, 2020 Filed Dec 9, 2020 01:37 UTC | Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772 | SaleCommon Stock | 2,153 | $54.39 | $117,093.70 |
DisclosureSEC source: 0001725160-20-000057 · wf-form4_160747776922044.xml · nonDerivative · entry 6 SUN ANTHONY Y · CIK 0001377952 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,017,605 F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading arrangement adopted by the Reporting Person. Shares sold to satisfy withholding tax obligations upon the vesting of restricted stock units. F7 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $54.15 to $54.89. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| December 07, 2020 Filed Dec 9, 2020 01:37 UTC | Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772 | SaleCommon Stock | 27,446 | $53.71 | $1,474,154.85 |
DisclosureSEC source: 0001725160-20-000057 · wf-form4_160747776922044.xml · nonDerivative · entry 5 SUN ANTHONY Y · CIK 0001377952 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,019,758 F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading arrangement adopted by the Reporting Person. Shares sold to satisfy withholding tax obligations upon the vesting of restricted stock units. F6 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $53.15 to $54.14. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| December 07, 2020 Filed Dec 9, 2020 01:37 UTC | Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772 | SaleCommon Stock | 5,350 | $52.53 | $281,031.76 |
DisclosureSEC source: 0001725160-20-000057 · wf-form4_160747776922044.xml · nonDerivative · entry 4 SUN ANTHONY Y · CIK 0001377952 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,047,204 F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading arrangement adopted by the Reporting Person. Shares sold to satisfy withholding tax obligations upon the vesting of restricted stock units. F5 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $52.15 to $53.13. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| December 07, 2020 Filed Dec 9, 2020 01:37 UTC | Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772 | SaleCommon Stock | 657 | $50.84 | $33,401.22 |
DisclosureSEC source: 0001725160-20-000057 · wf-form4_160747776922044.xml · nonDerivative · entry 3 SUN ANTHONY Y · CIK 0001377952 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,052,554 F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading arrangement adopted by the Reporting Person. Shares sold to satisfy withholding tax obligations upon the vesting of restricted stock units. F4 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $50.53 to $51.50. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| December 04, 2020 Filed Dec 9, 2020 01:37 UTC | Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772 | SaleCommon Stock | 21,356 | $51.17 | $1,092,846.32 |
DisclosureSEC source: 0001725160-20-000057 · wf-form4_160747776922044.xml · nonDerivative · entry 2 SUN ANTHONY Y · CIK 0001377952 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,053,211 F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading arrangement adopted by the Reporting Person. Shares sold to satisfy withholding tax obligations upon the vesting of restricted stock units. F3 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $51.02 to $52.00. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| December 04, 2020 Filed Dec 9, 2020 01:37 UTC | Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772 | SaleCommon Stock | 18,413 | $50.76 | $934,693.60 |
DisclosureSEC source: 0001725160-20-000057 · wf-form4_160747776922044.xml · nonDerivative · entry 1 SUN ANTHONY Y · CIK 0001377952 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,074,567 F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading arrangement adopted by the Reporting Person. Shares sold to satisfy withholding tax obligations upon the vesting of restricted stock units. F2 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $50.02 to $51.01. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| December 02, 2020 Filed Dec 3, 2020 22:56 UTC | Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772 | SaleCommon Stock | 6,283 | $52.70 | $331,122.90 |
DisclosureSEC source: 0001725160-20-000049 · wf-form4_160703617839290.xml · nonDerivative · entry 4 SUN ANTHONY Y · CIK 0001377952 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,092,980 F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 22, 2020. F5 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $52.37 to $53.21. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| December 02, 2020 Filed Dec 3, 2020 22:56 UTC | Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772 | SaleCommon Stock | 7,878 | $51.67 | $407,021.60 |
DisclosureSEC source: 0001725160-20-000049 · wf-form4_160703617839290.xml · nonDerivative · entry 3 SUN ANTHONY Y · CIK 0001377952 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,099,263 F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 22, 2020. F4 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $51.36 to $52.19. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| December 02, 2020 Filed Dec 3, 2020 22:56 UTC | Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772 | SaleCommon Stock | 9,222 | $50.90 | $469,361.07 |
DisclosureSEC source: 0001725160-20-000049 · wf-form4_160703617839290.xml · nonDerivative · entry 2 SUN ANTHONY Y · CIK 0001377952 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,107,141 F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 22, 2020. F3 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $50.36 to $51.34. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| December 02, 2020 Filed Dec 3, 2020 22:56 UTC | Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772 | SaleCommon Stock | 3,411 | $49.79 | $169,838.12 |
DisclosureSEC source: 0001725160-20-000049 · wf-form4_160703617839290.xml · nonDerivative · entry 1 SUN ANTHONY Y · CIK 0001377952 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,116,363 F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 22, 2020. F2 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $49.34 to $50.30. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| November 24, 2020 Filed Nov 26, 2020 01:34 UTC | Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772 | SaleCommon Stock | 100 | $47.56 | $4,756.00 |
DisclosureSEC source: 0001725160-20-000040 · wf-form4_160635443646975.xml · nonDerivative · entry 6 SUN ANTHONY Y · CIK 0001377952 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,119,774 F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 22, 2020. Read SEC document |
| November 24, 2020 Filed Nov 26, 2020 01:34 UTC | Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772 | SaleCommon Stock | 5,455 | $46.68 | $254,663.95 |
DisclosureSEC source: 0001725160-20-000040 · wf-form4_160635443646975.xml · nonDerivative · entry 5 SUN ANTHONY Y · CIK 0001377952 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,119,874 F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 22, 2020. F5 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $46.42 to $47.09. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| November 24, 2020 Filed Nov 26, 2020 01:34 UTC | Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772 | SaleCommon Stock | 5,831 | $46.21 | $269,424.27 |
DisclosureSEC source: 0001725160-20-000040 · wf-form4_160635443646975.xml · nonDerivative · entry 4 SUN ANTHONY Y · CIK 0001377952 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,125,329 F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 22, 2020. F4 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $45.42 to $46.41. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| November 23, 2020 Filed Nov 26, 2020 01:34 UTC | Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772 | SaleCommon Stock | 1,712 | $47.19 | $80,791.51 |
DisclosureSEC source: 0001725160-20-000040 · wf-form4_160635443646975.xml · nonDerivative · entry 3 SUN ANTHONY Y · CIK 0001377952 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,131,160 F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 22, 2020. F3 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $47.01 to $47.65. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| November 23, 2020 Filed Nov 26, 2020 01:34 UTC | Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772 | SaleCommon Stock | 13,696 | $46.45 | $636,128.52 |
DisclosureSEC source: 0001725160-20-000040 · wf-form4_160635443646975.xml · nonDerivative · entry 2 SUN ANTHONY Y · CIK 0001377952 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,132,872 F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 22, 2020. F2 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $45.99 to $46.97. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| November 22, 2020 Filed Jan 7, 2021 01:25 UTC | Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772 | GiftCommon Stock | 213,600 | $0.00 | $0.00 |
DisclosureSEC source: 0001725160-21-000008 · wf-form4_160998272301109.xml · nonDerivative · entry 2 SUN ANTHONY Y · CIK 0001377952 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 213,600 F1 · ownership.nature: Represents shares nominally held by Hao Bao Zi Trust LLC on behalf of the Hao Bao Zi Trust (the "Trust"), the sole member of Hao Bao Zi Trust LLC. The Reporting Person's spouse is the investment adviser with sole power to make investment decisions regarding the securities held by the Trust. The Reporting Person disclaims beneficial ownership of the securities held by Hao Bao Zi Trust LLC except to the extent of his pecuniary interest therein, if any. Read SEC document |
| November 22, 2020 Filed Jan 7, 2021 01:25 UTC | Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772 | GiftCommon Stock | 213,600 | $0.00 | $0.00 |
DisclosureSEC source: 0001725160-21-000008 · wf-form4_160998272301109.xml · nonDerivative · entry 1 SUN ANTHONY Y · CIK 0001377952 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,804,005 Read SEC document |
| September 11, 2020 Filed Sep 15, 2020 16:16 UTC | HYPERION DEFI, INC. EYEN · Entity 7220 | GrantStock Option (right to buy) · Derivative | 9,820 | $0.00 Strike: $3.43 | $0.00 |
DisclosureSEC source: 0001104659-20-105234 · tm2030853d3_4.xml · derivative · entry 2 SUN ANTHONY Y · CIK 0001377952 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,820 Underlying: Common Stock · 9,820 shares Expires 2030-09-11 F2 · derivative.exercise_date: The option becomes exercisable on the earlier of September 11, 2021 or the date of the Issuer's 2021 annual meeting of stockholders, subject to the Reporting Person's continued service on the Issuer's Board of Directors and acceleration upon change in control. Read SEC document |
| September 11, 2020 Filed Sep 15, 2020 16:16 UTC | HYPERION DEFI, INC. EYEN · Entity 7220 | GrantCommon Stock, par value $.0001 | 7,288 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-20-105234 · tm2030853d3_4.xml · nonDerivative · entry 1 SUN ANTHONY Y · CIK 0001377952 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,359 F1 · shares: Represents restricted stock units that vest on the earlier of September 11, 2021 or the date of the Issuer's 2021 annual meeting of stockholders, subject to the Reporting Person's continued service on the Issuer's Board of Directors and acceleration upon change in control. Read SEC document |
| April 07, 2020 Filed Apr 9, 2020 20:31 UTC | Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772 | GrantCommon Stock | 303,392 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-20-010606 · doc4.xml · nonDerivative · entry 1 SUN ANTHONY Y · CIK 0001377952 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,145,680 F1 · shares: Represents restricted stock units, each of which represent a contingent right to receive one share of common stock, and which will vest over a fifteen month period following the grant date. Read SEC document |
| April 07, 2020 Filed Nov 26, 2020 01:34 UTC | Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772 | PurchaseCommon Stock | 888 | $18.00 | $15,984.00 |
DisclosureSEC source: 0001725160-20-000040 · wf-form4_160635443646975.xml · nonDerivative · entry 1 SUN ANTHONY Y · CIK 0001377952 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,146,568 Read SEC document |
| August 16, 2019 Filed Aug 20, 2019 17:21 UTC | HYPERION DEFI, INC. EYEN · Entity 7220 | GrantStock Option (right to buy) · Derivative | 9,057 | $0.00 Strike: $3.11 | $0.00 |
DisclosureSEC source: 0001638599-19-000796 · doc4_6258.xml · derivative · entry 2 SUN ANTHONY Y · CIK 0001377952 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,057 Underlying: Common Stock · 9,057 shares Expires 2029-08-16 F2 · derivative.exercise_date: The option becomes exercisable on the earlier of August 16, 2020 or the date of the Issuer's 2020 annual meeting of stockholders, subject to the Reporting Person's continued service on the Issuer's Board of Directors and acceleration upon change in control. Read SEC document |
| August 16, 2019 Filed Aug 20, 2019 17:21 UTC | HYPERION DEFI, INC. EYEN · Entity 7220 | GrantCommon Stock, par value $.0001 | 8,038 | $0.00 | $0.00 |
DisclosureSEC source: 0001638599-19-000796 · doc4_6258.xml · nonDerivative · entry 1 SUN ANTHONY Y · CIK 0001377952 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,071 F1 · shares: Represents restricted stock units that vest on the earlier of August 16, 2020 or the date of the Issuer's 2020 annual meeting of stockholders, subject to the Reporting Person's continued service on the Issuer's Board of Directors and acceleration upon change in control. Read SEC document |
| July 24, 2018 Filed Jul 30, 2018 17:20 UTC | HYPERION DEFI, INC. EYEN · Entity 7220 | GrantStock Option (right to buy) · Derivative | 4,465 | $0.00 Strike: $6.20 | $0.00 |
DisclosureSEC source: 0001638599-18-000864 · doc4_5550.xml · derivative · entry 2 SUN ANTHONY Y · CIK 0001377952 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,465 Underlying: Common Stock · 4,465 shares Expires 2028-07-24 F2 · derivative.exercise_date: The option becomes exercisable on the earlier of July 24, 2019 or the date of the Issuer's 2019 annual meeting of stockholders, subject to the Reporting Person's continued service on the Issuer's Board of Directors and acceleration upon change in control. Read SEC document |
| July 24, 2018 Filed Jul 30, 2018 17:20 UTC | HYPERION DEFI, INC. EYEN · Entity 7220 | GrantCommon Stock, par value $.0001 | 4,033 | $0.00 | $0.00 |
DisclosureSEC source: 0001638599-18-000864 · doc4_5550.xml · nonDerivative · entry 1 SUN ANTHONY Y · CIK 0001377952 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,033 F1 · shares: Represents restricted stock units that vest on the earlier of July 24, 2019 or the date of the Issuer's 2019 annual meeting of stockholders, subject to the Reporting Person's continued service on the Issuer's Board of Directors and acceleration upon change in control. Read SEC document |
| December 20, 2017 Filed Dec 22, 2017 17:10 UTC | Aravive, Inc. VSAR · Entity 114535 | GrantCommon Stock | 11,200 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-067109 · doc4.xml · nonDerivative · entry 1 SUN ANTHONY Y · CIK 0001377952 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,880 F1 · shares: Represents the grant of restricted stock units that vest 100% on December 20, 2018. Read SEC document |
| May 25, 2017 Filed Jun 6, 2017 19:59 UTC | Aravive, Inc. VSAR · Entity 114535 | GrantStock Option (Right to Buy) · Derivative | 6,850 | $0.00 Strike: $15.83 | $0.00 |
DisclosureSEC source: 0001209191-17-038230 · doc4.xml · derivative · entry 2 SUN ANTHONY Y · CIK 0001377952 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,850 Underlying: Common Stock · 6,850 shares Expires 2027-05-24 F2 · derivative.exercise_date: The shares shall vest fully on the earlier of (a) the next annual stockholder meeting held after May 25, 2017 and (b) May 25, 2018. Read SEC document |
| May 25, 2017 Filed Jun 6, 2017 19:59 UTC | Aravive, Inc. VSAR · Entity 114535 | GrantCommon Stock | 3,480 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-038230 · doc4.xml · nonDerivative · entry 1 SUN ANTHONY Y · CIK 0001377952 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,680 F1 · shares: Represents the grant of restricted stock units that vest fully on the earlier of (a) the next annual stockholder meeting held after May 25, 2017 and (b) May 25, 2018. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.